டோங்கா மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from டோங்கா மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In டோங்கா மருந்து Today - Breaking & Trending Today
Posted : 2021-03-08 15:28 Updated : 2021-03-08 18:28 Dong-A Pharmaceutical CEO Choi Ho-jin appears on the YouTube channel, Nego(tiation) King, on which the firm s feminine hygiene products were featured. After the episode was aired Friday, however, the firm has been embroiled in a controversy over sexism during its recruitment practices following accusations made by a former job applicant. Captured from YouTube By Jun Ji-hye Dong-A Pharmaceutical is facing criticism online over allegations that its human resources staff asked female applicants sexist questions during job interviews last year. The CEO has made a public apology, but criticism has not abated, with the company even facing the threat of a boycott. ....
Share this article Share this article ResearchAndMarkets.com s offering. The global drugs for erectile dysfunction market is expected to decline from $5 billion in 2019 to $3.4 billion in 2020 at a compound annual growth rate (CAGR) of -32.5%. The decline is mainly due to the disruption caused by the lockdown measure across various countries to contain COVID-19 spread. The erectile dysfunction (ED) drugs market consists of sales of erectile dysfunction (ED) drugs and related services. Erectile dysfunction is the inability to achieve or keep up penile erection in men. Currently there is less demand for genito-urinary drugs mainly as people are staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow at a CAGR of 3.7% from 2021 and reach $5.7 billion in 2023. ....
Immunoforge s PF1801 Is Designated as Orphan Drug by FDA News provided by Share this article Share this article SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for treatment of the Duchenne muscular dystrophy on January 25. As the orphan drug designation awardee, Immunoforge will be granted the following benefits from the FDA: waiver of qualified clinical trials costs and FDA expedited review during clinical trials for the Duchenne muscular dystrophy, as well as 7-years of exclusive right on marketing upon market approval. ....
Erectile Dysfunction Shockwave Generators Market Future openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.